Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% - Here's What Happened
Kalaris Therapeutics (NASDAQ:KLRS) saw its shares jump 15.4% to $4.05 in midday trading, despite lower-than-average trading volume. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $18.75. Insider activity shows Director Srinivas Akkaraju recently purchased 244,300 shares, increasing his holdings …